Press Releases

Date Title and Summary View
Toggle Summary MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Study Met Primary and Key Secondary Endpoints with Statistically Significant Results  Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical Standard-of Care No Deleterious Effect on Wound Closure and No Observed Safety Issues End of Phase 2 Meeting
View HTML
Toggle Summary MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
YAVNE, Israel , May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
The poster, featuring the phase 2 pharmacology study promising results, was selected and featured during the Grand Rounds Session of the SAWC Wound Care Learning Network YAVNE, Israel , April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company
View HTML
Toggle Summary MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel , March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic
View HTML
Toggle Summary MediWound Announces Exercise of Over-Allotment Option
YAVNE, Israel, March 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that the underwriter of its
View HTML
Toggle Summary MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
Primary Endpoint Met with Highly Statistically Significant Results Final Data Readout Expected in Second Quarter of 2022 YAVNE, Israel , March 21, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
Full-Year 2021 Total Revenues of $23.8 Million ; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Offering Conference Call Begins Today at 8:30 am ET  
View HTML
Toggle Summary MediWound Announces Closing of Public Offering of Ordinary Shares
YAVNE, Israel , March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that on March 7, 2022 it
View HTML
Toggle Summary MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
YAVNE, Israel , March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound Announces Pricing of Public Offering of Ordinary Shares
YAVNE, Israel , March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the pricing of an
View HTML